Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CQ72 | ISIN: US1523091007 | Ticker-Symbol: 260
Stuttgart
15.05.25 | 08:06
10,800 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
CENTESSA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
CENTESSA PHARMACEUTICALS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
11,10011,30019:56
11,10011,30019:50

Aktuelle News zur CENTESSA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCentessa Pharmaceuticals GAAP EPS of -$0.20 beats by $0.15, revenue of $15M1
MiCentessa Pharmaceuticals plc - 10-Q, Quarterly Report2
MiCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025312Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy...
► Artikel lesen
MiCentessa Pharmaceuticals plc - 8-K, Current Report3
08.05.This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday2
31.03.Piper Sandler sets Centessa stock with $38 target, Overweight rating3
25.03.BMO Capital maintains $35 target on Centessa, cites ORX750 potential2
CENTESSA PHARMACEUTICALS Aktie jetzt für 0€ handeln
24.03.Centessa Pharmaceuticals plc - S-8, Securities to be offered to employees in employee benefit plans1
24.03.Centessa Pharmaceuticals plc - 10-K, Annual Report2
24.03.Centessa Pharmaceuticals plc - 8-K, Current Report4
24.03.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024351Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type...
► Artikel lesen
06.03.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting1
05.03.TD Cowen reiterates buy on Centessa stock, sees upside1
21.02.Centessa Pharmaceuticals plc - 8-K, Current Report-
14.02.Centessa Pharmaceuticals plc - 10-Q/A, Quarterly Report-
13.01.Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?2
08.01.Centessa Pharmaceuticals names Stephen Kanes as chief medical officer1
08.01.Centessa Pharmaceuticals ernennt neuen Chief Medical Officer2
08.01.Centessa Pharmaceuticals appoints new Chief Medical Officer1
08.01.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer218BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1